420 related articles for article (PubMed ID: 19330495)
1. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial.
Knapp M; Romeo R; Mogg A; Eranti S; Pluck G; Purvis R; Brown RG; Howard R; Philpot M; Rothwell J; Edwards D; McLoughlin DM
J Affect Disord; 2008 Aug; 109(3):273-85. PubMed ID: 18262655
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
6. Gender patterns in cost effectiveness of quality improvement for depression: results of a randomized, controlled trial.
Schoenbaum M; Sherbourne C; Wells K
J Affect Disord; 2005 Aug; 87(2-3):319-25. PubMed ID: 16005520
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care.
Stant AD; TenVergert EM; Kluiter H; Conradi HJ; Smit A; Ormel J
J Ment Health Policy Econ; 2009 Dec; 12(4):195-204. PubMed ID: 20195007
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
Borg S; Glenngård AH; Osterborg A; Persson U
Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
[TBL] [Abstract][Full Text] [Related]
10. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
11. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
13. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
Stylopoulos N; Gazelle GS; Rattner DW
Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for depression treatment programs and willingness to pay for treatment.
Morey E; Thacher JA; Craighead WE
J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model.
Aziz M; Mehringer AM; Mozurkewich E; Razik GN
Can J Psychiatry; 2005 Jun; 50(7):389-97. PubMed ID: 16086536
[TBL] [Abstract][Full Text] [Related]
16. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
17. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
20. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
